Compare SOTK & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ECOR |
|---|---|---|
| Founded | 1975 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 81.0M |
| IPO Year | 1995 | 2018 |
| Metric | SOTK | ECOR |
|---|---|---|
| Price | $5.17 | $6.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 52.4K | ★ 81.0K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | $20,909,315.00 | ★ $32,032,000.00 |
| Revenue This Year | $4.02 | $33.60 |
| Revenue Next Year | $10.95 | $30.40 |
| P/E Ratio | $105.00 | ★ N/A |
| Revenue Growth | 1.97 | ★ 27.20 |
| 52 Week Low | $3.23 | $4.16 |
| 52 Week High | $6.24 | $10.50 |
| Indicator | SOTK | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 38.61 |
| Support Level | $5.01 | $5.69 |
| Resistance Level | $5.72 | $7.35 |
| Average True Range (ATR) | 0.39 | 0.66 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 17.89 | 17.60 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.